In pan-cancer patients, the proportion of heterozygous CNV for KCC2 and NKCC1 is extraordinarily high, and KCC2 is mainly a form of heterozygous amplification, while NKCC1 is mainly a form of heterozygous deletion. The gene discussed is SLC12A5; the disease is cancer.